Therapeutic antibodies are increasingly being used in the clinic for the treatment of various diseases. Yet, oral to gut targeting of antibodies remains a challenge due to their incapability to survive digestion and reach gastrointestinal tissues. Now, scientists have developed a new antibody technology that combines the advantages of antibody-based therapies with the convenience of oral drug administration. Importantly, these antibodies are manufactured using yeast in a process as straight-forward as food-manufacturing. This work was published today in the journal Nature Biotechnology and is the result of an ongoing collaborative effort between Nico Callewaert (VIB-UGent Center for Medical Biotechnology), Ann Depicker (VIB-UGent Center for Plant Systems Biology), Henri De Greve (VIB-VUB Center for Structural Biology) and Eric Cox (UGent Faculty of Veterinary Medicine). The antibody technology may have potential uses in various areas, from fighting veterinary and human gut infections, treating inflammatory and metabolic disorders, to the development of microbiome altering food supplements.
Edible antibodies to treat and prevent gastrointestinal disorders
Conventional therapeutic antibodies are injected into the bloodstream for treatment or prevention of a multitude of diseases, including infectious diseases, cancer and inflammation. While widely applicable, these antibody-based therapies are not designed for oral ingestion for targets in the gut, as the digestive environment of gastrointestinal tract may break it down. In addition to avoiding needles, local delivery of antibodies rather than systemic administration can be preferred to minimize or even avoid systemic side effects. That’s why scientists are working on technologies that protect antibodies during gastric passage to deliver them intact to the target site in the gut.
Now, research by Vikram Virdi, postdoc in the lab of Nico Callewaert (VIB-UGent) and Ann Depicker (VIB-UGent), makes oral to gut delivery of antibodies possible. The scientists engineered an antibody format that is simple but robust enough to survive the harsh environment in the gut. What is more, the team also developed a manufacturing process that uses either soybean seeds or yeast cells to produce these antibodies. By using existing food-processing technology they could eliminate the need for expensive purification processes. The result is an easily manufactured powder with antibodies that can be added to food and ingested orally, requiring no encapsulation.
In collaboration with the group of Eric Cox (UGent), the scientists obtained proof-of-concept with the technology in one of the target species, young piglets susceptible to a diarrhea-causing infection. Post-weaning diarrhea caused by enterotoxigenic Escherichia coli (ETEC) is an economically important disease in pig production worldwide. At the moment the only thing that helps against this infection is the use of antibiotics, which is a risk factor for the well-known problems of antibiotic resistance and potential transmission of resistant bacteria between animals and humans. This is a huge conundrum for pig producers, how to overcome ETEC crises in the face of strict regulatory limitations on the use of antibiotics for livestock. The new antibody-based approach appeared an effective and safe alternative. “The piglets, which were provided food supplemented with the new antibodies,” Vikram Virdi says, “were protected against infection by ETEC in a pilot study.” Given these results, the team is looking to further develop the antibodies as veterinary product.
Yet according to Nico Callewaert, who led the yeast work, the applications go much further. “Since the human and pig gut is strikingly similar, the lab is already exploring this technology for preventing and treating human gut infections and reducing symptoms in gastric diseases such as Crohn’s disease and ulcerative colitis. One of the key contributions may be in humanitarian projects, for example during post-disaster situations to combat outbreaks of gut diseases such as cholera caused diarrhea.” Overall, the versatility of this new technology creates novel product opportunities for use in different sectors, like food and feed additives, nutraceuticals, biopharmaceuticals, and microbiome optimization.
Yeast-secreted, dried and food-admixed monomeric IgA prevents gastrointestinal infection in a piglet model, Virdi et al., Nature Biotechnology 2019
Questions from patients
A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. That is why we ask you to please refer questions in your report or article to the email address that VIB makes available for this purpose: email@example.com. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.